Zinnat | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Zinnat
Health Canada Patents

Veranova: A CDMO that manages complexity with confidence.

Contact Supplier

Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Contact Supplier

pharmacompass-1-m-2025-08-25

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Zinnat

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

67 API Suppliers, 38 USDMF, 20 CEP/COS, 9 EU WC, 22 KDMF, 4 NDC API, 16 Listed Suppliers, $ API Reference Price

67 API Suppliers
38 USDMF
20 CEP/COS
9 EU WC
22 KDMF
4 NDC API
16 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

FINISHED DOSAGE FORMULATIONS

255 FDF Dossiers, 34 FDA Orange Book, 112 Europe, 7 Canada, 9 South Africa, 93 Listed Dossiers

255 FDF Dossiers
34 FDA Orange Book
112 Europe
7 Canada
9 South Africa
93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML, FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML
FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

RELATED EXCIPIENT COMPANIES

3 Evonik, 4 Rochem International Inc, 20 SPI Pharma, 9 DKSH, 1 Pharm-RX Chemical, 3 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 Kirsch Pharma, 1 ACG Worldwide, 8 Actylis, 2 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 19 BASF, 1 CD Formulation, 2 Clariant, 12 Corel Pharma Chem, 3 DFE Pharma, 1 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 8 Ideal Cures, 4 Ingredion Pharma Solutions, 11 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 20 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

61 Fillers, Diluents & Binders, 52 Coating Systems & Additives, 31 Thickeners and Stabilizers, 30 Direct Compression, 26 Controlled & Modified Release, 26 Lubricants & Glidants, 24 Solubilizers, 23 Taste Masking, 21 Topical, 21 Chewable & Orodispersible Aids, 21 Disintegrants & Superdisintegrants, 19 Granulation, 18 Parenteral, 15 Film Formers & Plasticizers, 15 Co-Processed Excipients, 11 Emulsifying Agents, 10 Rheology Modifiers, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents

61 Fillers, Diluents & Binders
52 Coating Systems & Additives
31 Thickeners and Stabilizers
30 Direct Compression
26 Controlled & Modified Release
26 Lubricants & Glidants
24 Solubilizers
23 Taste Masking
21 Topical
21 Chewable & Orodispersible Aids
21 Disintegrants & Superdisintegrants
19 Granulation
18 Parenteral
15 Film Formers & Plasticizers
15 Co-Processed Excipients
11 Emulsifying Agents
10 Rheology Modifiers
7 API Stability Enhancers
6 Surfactant & Foaming Agents
5 Empty Capsules
4 Vegetarian Capsules
4 Coloring Agents

DIGITAL CONTENT

11 News #PharmaBuzz

11 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 112 Regulatory FDF Prices

7 US Medicaid Prescriptions
112 Regulatory FDF Prices

MARKET PLACE

26 APIs, 30 FDF Dossiers

26 APIs
30 FDF Dossiers

PATENTS & EXCLUSIVITIES

9 Health Canada Patents

9 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 5 Others

1 EDQM
1 USP
5 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 131 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2GlaxoSmithKline Inc.

filter Patent Reset all filters

2 All

01 11328405

02 12408198

filter Product Reset all filters

2 All

01 2Cefuroxime Axetil

filter Dosage Reset all filters

2 All

01 2Granules for Suspension

filter Exp Date Reset all filters

2 All

01 12011-04-12

02 12022-11-21

Product Main Page

01

GlaxoSmithKline Inc.

Cefuroxime Axetil

CPhI Korea

Not Confirmed

GlaxoSmithKline Inc.

CPhI Korea

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-11-21

Date Granted : 2004-03-09

Cefuroxime Axetil

Brand Name : CEFTIN

Patent Number : 2408198

Filing Date : 2002-11-21

Strength per Unit : 125mg / 5ml

Dosage Form : Granules for Suspension

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-11-21

Date Granted : 2004-03-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Cefuroxime Axetil

CPhI Korea

Not Confirmed

GlaxoSmithKline Inc.

CPhI Korea

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-04-12

Date Granted : 1994-04-12

Cefuroxime Axetil

Brand Name : CEFTIN

Patent Number : 1328405

Filing Date : 1988-05-13

Strength per Unit : 125mg / 5ml

Dosage Form : Granules for Suspension

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-04-12

Date Granted : 1994-04-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!